Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of 404 common shares worth $20,159.6
Reuters2026/08/20 20:09Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 404 common shares on Aug. 19, 2026 at USD 49.9.
- Direct holdings fell to 246,022 shares following the transaction.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-359189), on August 20, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ondas director Richard M. Cohen disposes of 7,500 common shares worth $67,177.50
Reuters•2026/08/20 21:09
HBR Realty publishes independent auditor review report for June 30, 2026 interim financials
Reuters•2026/08/20 21:08
BorgWarner Director Rajesh Kalathur acquires 7,407 common shares for $500,035.51
Reuters•2026/08/20 21:08
Cury investor relations chief joins Bastter online event to present company overview
Reuters•2026/08/20 21:08
